Race and ethnicity do not impact eligibility for remdesivir: A single-center experience

PLoS One. 2021 May 6;16(5):e0250735. doi: 10.1371/journal.pone.0250735. eCollection 2021.

Abstract

As the Coronavirus-2019 (COVID-19) pandemic continues, multiple therapies are rapidly being evaluated for efficacy in clinical trials. Clinical trials should be racially and ethnically representative of the population that will eventually benefit from these medications. There are multiple potential barriers to racial and ethnic minority enrollment in clinical trials, one of which could be that inclusion and exclusion criteria select for certain racial or ethnic groups disproportionately. In this observational cohort study at a single health care system, we examined if there were differences in eligibility for treatment with remdesivir based on clinical trial criteria for racial and ethnic minorities compared to non-Hispanic Whites. 201 electronic medical record charts were reviewed manually. Self-identified Whites were older than other racial or ethnic groups. At the time of presentation, Black, Latinx, and White participants met inclusion criteria for remdesivir at similar rates (72%, 80%, and 73% respectively), and exclusion criteria at similar rates (43%, 38% and 49% for Black, Latinx and White participants respectively). In this study, there was no difference in eligibility for remdesivir based on race or ethnicity alone.

Publication types

  • Clinical Trial
  • Observational Study

MeSH terms

  • Adenosine Monophosphate / analogs & derivatives*
  • Adenosine Monophosphate / therapeutic use
  • Adult
  • Aged
  • Aged, 80 and over
  • Alanine / analogs & derivatives*
  • Alanine / therapeutic use
  • Antiviral Agents / therapeutic use*
  • Black or African American
  • COVID-19 Drug Treatment*
  • Delivery of Health Care
  • Eligibility Determination
  • Female
  • Hispanic or Latino
  • Humans
  • Male
  • Middle Aged
  • Minority Groups
  • SARS-CoV-2 / drug effects
  • United States / epidemiology
  • White People
  • Young Adult

Substances

  • Antiviral Agents
  • remdesivir
  • Adenosine Monophosphate
  • Alanine